drugset / Trial / NCT05860595
Evaluation the Safety and Efficacy of KL003 Cell Injection in the Treatment of Transfusion-dependent β-thalassemia.
Active not recruiting
3 enrolled
Institute of Hematology & Blood Diseases Hospital, China
R&D Kanglin Biotech · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, single-dose study. The aim of this study is to evaluate the safety and efficacy of the treatment with lentiviral vector encoding βA-T87Q-globin gene transduced autologous hematopoietic stem cells in subjects with transfusion-dependent β-thalassemia.
Timeline
- Start
- 2023-05-23
- Primary completion
- 2025-08-20
- Completion
- 2025-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KL003 | Cell therapy | — | — |